GlassScriptPhysician profile
Andrew J Cutler
NPI 1437159720
$72,271.45
in general payments reported to CMS, 2019-2025
39 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,789 · 2021: $3,891 · 2022: $21K · 2023: $13K · 2024: $8,492 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $27K · Food and Beverage: $3,777 · Travel and Lodging: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $27,040.00 |
| Food and Beverage | $3,776.73 |
| Travel and Lodging | $2,004.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $45,866.95 | 2020-2025 | Quillivant, Dyanavel Xr, Quillichew Er |
| Allergan, INC. | $8,118.75 | 2019 | |
| Abbvie INC. | $7,000.88 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Neurocrine Biosciences, INC. | $2,680.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,496.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $868.09 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $800.60 | 2019-2024 | Austedo Xr, Uzedy |
| Lilly USA, LLC | $634.45 | 2019-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $599.80 | 2019-2024 | |
| Amgen INC. | $511.52 | 2019-2024 | Prolia, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $498.59 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.50 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $357.33 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $322.50 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Axsome Therapeutics, INC. | $291.68 | 2024-2025 | Auvelity, Sunosi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cutler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.